Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2008-03-18
2008-03-18
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S085100, C424S085400, C530S350000, C530S351000
Reexamination Certificate
active
07344709
ABSTRACT:
The present invention relates to the use of recombinant IFN-beta for the production of a medicament for the treatment of HCV infection by subcutaneous administration to patients of Asian race, which failed to respond to a previous treatment with interferon-alpha, is herein reported. According to a preferred embodiment of the invention, this treatment can be better and further focused to those patients which after at least 4 weeks of initial treatment with IFN-beta show HCV RNA clearance.
REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 4737462 (1988-04-01), Mark et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4959314 (1990-09-01), Mark et al.
patent: 4965195 (1990-10-01), Namen et al.
patent: 5017691 (1991-05-01), Lee et al.
patent: RE33653 (1991-07-01), Mark et al.
patent: 5116943 (1992-05-01), Koths et al.
patent: WO 99/55377 (1999-11-01), None
Barbaro et al., “Intravenous Recombinant Interferon-Beta versus Interferon-Alpha-2b and Ribavirin in Combination for Short-Term Treatment of Chronic Hepatitis C Patients Not Responding to Interferon-Alpha,” Scandinavian Journal of Gastroenterology, vol. 34 No. 9, pp. 928-933 (Sep. 1999).
Buchwalder et al., “Pharmacokinetics and pharmacodyamics of IFN-beta1a in healthy volunteers,” Jouranl of Interferon and Cytokine Research, vol. 20 No. 10, pp. 857-866 (2000).
Cheng et al., “Racial differences in responses to interferon-β-1a in chronic hepatitis C unresponsive to interferon-α: A better response in Chinese patients,” Journal of Viral hepatits, vol. 11 No. 5, pp. 418-426 (Sep. 2004).
Kakumu et al., “A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C,” Gastroenterology, vol. 105 No. 2, pp. 507-512 (1993).
Alter, M. J. et al. “The Natural History of Community-Acquired Hepatitis C in the United States”The New England Journal of Medicine, 1992, pp. 1899-1905, vol. 327, No. 27.
Alter, M. J. et al. “The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994”The New England Journal of Medicine, 1999, pp. 556-562, vol. 341.
Bacon, B.R. et al. “Lymphoblastoid Interferon Improves Long-Term Response to a Six Month Course of Treatment when compared with Recombinant Interferon Alfa 2b: Results of an International Trial”Hepatology, 1995, p. 152A, vol. 22.
Bedossa, P. et al. “An Algorithm for the Grading of Activity in Chronic Hepatitis C”Hepatology, 1996, pp. 289-293, vol. 24, No. 2.
Bonkovsky, H. L. et al. “Iron and Chronic Viral Hepatitis”Hepatology, 1997, pp. 759-768, vol. 25.
Brand, C.M. et al. “Antibodies Developing Against a Single Recombinant Interferon Protein may Neutralize many other Interferon-α Subtypes”Journal of Interferon Research, 1993, pp. 121-125, vol. 13.
Cavalli-Sforza, L. “Genes, Peoples and Languages”Scientific American, Nov. 1991, pp. 72-78.
Conjeevaram, H. S. et al. “Predictors of a Sustained Beneficial Response to Interferon Alfa Therapy in Chronic Hepatitis C”Hepatology, 1995, pp. 1326-1329, vol. 22, No. 4.
Cuzick, J. “A Wilcoxon-Type Test for Trend”Statistics In Medicine, 1985, pp. 87-90, vol. 4.
Davis, G. L. “Recombinant α-interferon Treatment of Non-A, Non-B (Type C) Hepatitis: Review of Studies and Recommendations for Treatment”Journal of Hepatology, 1990, pp. S72-S77, vol. 11.
Derynck, R. et al. “Isolation and Structure of a Human Fibroblast Interferon Gene”Nature, 1980, pp. 542-547, vol. 285.
Douglas, D. D. et al. “Randomized Controlled Trial of Recombinant Alpha-2a-Interferon for Chronic Hepatitis C. Comparison of Alanine Aminotransferase Normalization versus Loss of HCV RNA and Anti-HCV IgM”Digestive Diseases and Sciences, 1993, pp. 601-607, vol. 38, No. 4.
“NIH Recommends 12-month Interferon Therapy for Hepatitis C”Scrip, No. 2221, Apr. 8, 1997, pp. 25-26, PJB Publications Ltd.
Habersetzer, F. et al. “A Pilot Study of Recombinant Interferon Beta-1a for the Treatment of Chronic Hepatitis C”Liver, 2000, pp. 437-441, vol. 20.
Hoofnagle, J. H. et al. “The Treatment of Chronic Viral Hepatitis”The New England Journal of Medicine Drug Therapy, 1997, pp. 347-356, vol. 336, No. 5.
Ishak, K. et al. “Histological Grading and Staging of Chronic Hepatitis”Journal of Hepatology, 1995, pp. 696-699, vol. 22.
Kishihara, Y. et al. “A Preliminary Study of Retreatment of Chronic Hepatitis C with Interferon”Fukuoka Acta Med., 1995, pp. 113-120, vol. 86, No. 4.
Lindsay, K. L. et al. “Response to Higher Doses of Interferon Alfa-2b in Patients with Chronic Hepatitis C: A Randomized Multicenter Trial”Hepatology, 1996, pp. 1034-1040, vol. 24.
Lok, A. S-F. et al. “Interferon Antibodies may Negate the Antiviral Effects of Recombinant α-Interferon Treatment in Patients with Chronic Hepatitis B Virus Infection”Hepatology, 1990, pp. 1266-1270, vol. 12, No. 6.
Mark, D. F. et al. “Site-Specific Mutagenesis of the Human Fibroblast Interferon Gene”Proc. Natl. Acad. Sci. USA, Sep. 1984, pp. 5662-5666. vol. 81.
McCaughan, G. W. “Working Party Report: Hepatitis. Asian Perspectives on Viral Hepatitis: Hepatitis C Virus Infection”Journal of Gastroenterology and Hepatology, 2000, pp. G90-G93, vol. 15.
McHutchison, J. G. et al. “Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C”The New England Journal of Medicine, 1998, pp. 1485-1492, vol. 339, No. 21.
McIntyre N. et al. “Cirrhosis, Portal Hypertension and Ascites” In Weatherall DJ. et. al., editors.Oxford Textbook of Medicine, Chapter 14.29, 1996, pp. 2085-2100, Oxford University Press.
McOmish, F. et al. “Geographical Distribution of Hepatitis C Virus Genotypes in Blood Donors: an International Collaborative Survey”Journal of Clinical Microbiology, Apr. 1994, pp. 884-892, vol. 32, No. 4.
Milella, M. et al. “Neutralizing Antibodies to Recombinant Alpha-Interferon and Response to Therapy in Chronic Hepatitis C Virus Infection”Liver, 1993, pp. 146-150, vol. 13.
O'Brien, P. C. “Procedures for Comparing Samples with Multiple Endpoints”Biometrics, 1984, pp. 1079-1087, vol. 40.
Omata, M. et al. “Resolution of Acute Hepatitis C after Therapy with Natural Beta Interferon”The Lancet, 1991, pp. 914-915, vol. 338.
Perez, R. et al. “Clinical Efficacy of Intramuscular Human Interferon-β vs Interferon-α2b for the Treatment of Chronic Hepatitis C”Journal of Viral Hepatitis, 1995, pp. 103-106, vol. 2.
Piccinino, F. et al. “Non Responders to Interferon Therapy among Chronic Hepatitis Patients Infected with Hepatitis C Virus”Arch. Virol. Suppl., 1993, pp. 257-263, vol. 8.
Poynard, T. et al. “Randomized Trial of Interferon α2b Plus Ribavirin for 48 Weeks or 24 Weeks versus Interferon α2b Plus Placebo for 48 Weeks for Treatment of Chronic Infection with Hepatitis C Virus”The Lancet, 1998, pp. 1426-1432, vol. 352.
Poynard, T. et. al. “Meta-Analysis of Interferon Randomized Trials in the Treatment of Viral Hepatitis C: Effects of Dose and Duration”Hepatology, 1996, pp. 778-789, vol. 24.
PRISMS Study Group “PRISMS-4: Long Term Efficacy of Interferon-β-1a in Relapsing MS”Neurology, Jun. 2001, pp. 1628-1636, vol. 56.
Saracco, G. et al. “Long-Term Follow-up of Patients with Chronic Hepatitis C Treated with Different Doses of Interferon-α2b”Hepatology, 1993, pp. 1300-1305, vol. 18, No. 6.
Scheuer, P. J. “Scoring of Liver Biopsies: Are we Doing it Right?”Journal of Gastroenterology&Hepatology, 1996, pp. 1141-1143, vol. 8, No. 12.
Schvarcz, R. et al. “A Randomized Controlled Open Study of Interferon Alpha-2b Treatment of Chronic Non-A, Non-B Posttransfusion Hepatitis: No Correlation of Outcome to Presence
Maschek Birgit
Parsons Ian
Wee Tit Gin Theodor
Laboratories Serono SA
Lucas Zachariah
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Treatment of hepatitis C in the Asian population with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hepatitis C in the Asian population with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hepatitis C in the Asian population with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2814518